The Assessment and Treatment of Antipsychotic-Induced Akathisia

Canadian Journal of Psychiatry

Volumn 63, Issue 11, 2018, Pages 719-729

  Pringsheim, Tamara ^a   Gardner, David ^b   Addington, Donald ^a   Martino, Davide ^c   Morgante, Francesca ^d,e   Ricciardi, Lucia ^e   Poole, Norman ^f   Remington, Gary ^g   Edwards, Mark ^e   Carson, Alan ^h   Barnes, Thomas R E ⁱ  

^a UNIVERSITY OF CALGARY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF MESSINA   (Italy)

^e ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF TORONTO   (Canada)

^h UNIVERSITY OF EDINBURGH   (United Kingdom)

ⁱ IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

antipsychotics; evidence based medicine; extrapyramidal syndromes

Indexed keywords

BENZATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIPERIDEN; CLONAZEPAM; CYPROHEPTADINE; MIANSERIN; MIRTAZAPINE; NEUROLEPTIC AGENT; PROPRANOLOL; PYRIDOXINE; SEROTONIN 2A ANTAGONIST; TRAZODONE;

AKATHISIA; CLINICAL ASSESSMENT; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; MEDICAL HISTORY; PERSONALIZED MEDICINE; POLYPHARMACY; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 85058672494     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/0706743718760288     Document Type: Review

References (85)

1. Haskovec L. L’akathisie. Revue Neurologique. 1901; 9: 1107–1109
2. Sigwald J, Grossiord A, PD. Le traitement de la maladie de Parkinson et des manifestations extrapyramidalles par Ie diethylaminoethyl n-thiophyenylamine (2987 RP): resultats d’une annre d’application. Revue Neurologique. 1947; 79: 683–687
3. Kruse W. Persistent muscular restlessness after phenothiazine treatment: report of 3 cases. Am J Psychiatry. 1960; 117: 152–153
4. Raskin DE. Akathisia: a side effect to be remembered. Am J Psychiatry. 1972; 129(3): 345–347
5. Van Putten T. The many faces of akathisia. Compr Psychiatry. 1975; 16(1): 43–47
6. Braude WM, Barnes TR, Gore SM. Clinical characteristics of akathisia. A systematic investigation of acute psychiatric inpatient admissions. Br J Psychiatry. 1983; 143: 139–150
7. Barnes TR, Braude WM. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry. 1985; 42(9): 874–878
8. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989; 154: 672–676
9. Raja M, Azzoni A, Lubich L. Aggressive and violent behavior in a population of psychiatric inpatients. Soc Psychiatry Psychiatr Epidemiol. 1997; 32(7): 428–434
10. Poyurovsky M. Acute antipsychotic-induced akathisia revisited. Br J Psychiatry. 2010; 196(2): 89–91
11. Dufresne RL, Wagner RL. Antipsychotic-withdrawal akathisia versus antipsychotic-induced akathisia: further evidence for the existence of tardive akathisia. J Clin Psychiatry. 1988; 49(11): 435–438
12. Lang AE. Withdrawal akathisia: case reports and a proposed classification of chronic akathisia. Mov Disord. 1994; 9(2): 188–192
13. Cerovecki A, Musil R, Klimke A. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs. 2013; 27(7): 545–572
14. Sachdev P. Research diagnostic criteria for drug-induced akathisia: conceptualization, rationale, and proposal. Psychopharmacology (Berl). 1994; 114(1): 181–186
15. Burke RE, Kang UJ, Jankovic J. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord. 1989; 4(2): 157–175
16. Munetz MR, Cornes CL. Akathisia, pseudoakathisia and tardive dyskinesia: clinical examples. Compr Psychiatry. 1982; 23(4): 345–352
17. Barnes TR. The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia. Psychiatr Dev. 1987; 5(4): 301–319
18. Havaki-Kontaxaki BJ, Kontaxakis VP, Christodoulou GN. Prevalence and characteristics of patients with pseudoakathisia. Eur Neuropsychopharmacol. 2000; 10(5): 333–336
19. Weiden PJ, Mann JJ, Haas GL. Clinical nonrecognition of antipsychotic-induced movement disorders: a cautionary study. Am J Psychiatry. 1987; 144(9): 1148–1153
20. Van Putten T, Marder SR. Behavioral toxicity of antipsychotic drugs. J Clin Psychiatry. 1987; 48(Suppl): 13–19
21. Barnes TR. Neuromuscular effects of antipsychotics: akathisia. In: Kane JM, Lieberman JA, editors. Adverse effects of psychotropic drugs. New York, NY: Guidford Press, 1992
22. Margolese HC, Chouinard G, Walters Larach V. Relationship between antipsychotic-induced alathisia and tardive dyskinesiai and suicidality in schizophrenia: impact of clozapine and olanzapine. Acta Psychiatrica Belgica. 2001; 101: 128–144
23. Reutfors J, Clapham E, Bahmanyar S. Suicide risk and antipsychotic side effects in schizophrenia: nested case-control study. Human Psychopharmacol. 2016; 31(4): 341–345
24. Seemuller F, Schennach R, Mayr A. Akathisia and suicidal ideation in first-episode schizophrenia. J Clin Psychopharmacol. 2012; 32(5): 694–698
25. Leong GB, Silva JA. Neuroleptic-Induced akathisia and voilence: a review. J Forensic Sci. 2003; 48(1): 187–189
26. Lima AR, Bacalcthuk J, Barnes TR. Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2004; (4): CD001946
27. Lima AR, Soares-Weiser K, Bacaltchuk J. Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2002; (1): CD001950
28. Lima AR, Weiser KV, Bacaltchuk J. Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2004; (1): CD003727
29. Rathbone J, Soares-Weiser K. Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2006; (4): CD003727
30. Alabed S, Latifeh Y, Mohammad HA. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2011; (4): CD000203
31. El-Sayeh HG, Lyra da Silva JP, Rathbone J. Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2006; (1): CD000458
32. Bhoopathi PS, Soares-Weiser K. Benzodiazepines for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2006; (3): CD000205
33. Soares-Weiser K, Maayan N, McGrath J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2011; (4): CD000209
34. Soares-Weiser K, Rathbone J. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev. 2006; (1): CD000459
35. Bhidayasiri R, Fahn S, Weiner W. Evidence-based guideline: treatment of tardive syndromes. Neurology. 2013; 81(5): 463–469
36. Pringsheim T, Doja A, Belanger S. Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. Paediatrics Child Health. 2011; 16(9): 590–598
37. Gervin M, Barnes TR. Assessment of drug-related movement disorders in schizophrenia. Adv Psychiatric Treat. 2000; 6(5): 332–343
38. COD G., A guide to the extrapyramidal side-effects of antipsychotic drugs. Cambridge: Cambridge University Press, 1999
39. Sweet RA, DeSensi EG, Zubenko GS. Reliability and applicability of movement disorder rating scales in the elderly. J Neuropsychiatry Clin Neurosci. 1993; 5(1): 56–60
40. Loonen AJ, Doorschot CH, van Hemert DA. The schedule for the assessment of drug-induced movement disorders (SADIMoD): test-retest reliability and concurrent validity. Int J Neuropsychopharmcol. 2000; 3(4): 285–296
41. Barnes TR. The barnes akathisia rating scale - revisited. J Psychopharmacol. 2003; 17(4): 365–370
42. Janno S, Holi MM, Tuisku K. Actometry and barnes akathisia rating scale in antipsychotic-induced akathisia. Eur Neuropsychopharmacol. 2005; 15(1): 39–41
43. Chouinard G, Margolese HC. Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr Res. 2005; 76(2-3): 247–65
44. Miller CH, Hummer M, Oberbauer H. Risk factors for the development of antipsychotic induced akathisia. Eur Neuropsychopharmacol. 1997; 7(1): 51–55
45. Berna F, Misdrahi D, Boyer L. Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset. Schizophr Res. 2015; 169(1-3): 255–261
46. CADTH. Optimal use report: optimal use recommendations for atypical antipsychotics: combination and high-dose treatment strategies in adolescents and adults with schizophrenia. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health Care, 1: 2011
47. Essock SM, Schooler NR, Stroup TS. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry. 2011; 168(7): 702–708
48. Rummel-Kluge C, Komossa K, Schwarz S. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophrenia Bull. 2012; 38(1): 167–177
49. Haddad PM, Das A, Keyhani S. Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons. J Psychopharmacol. 2012; 26(5 suppl): 15–26
50. Thomas JE, Caballero J, Harrington CA. The incidence of akathisia in the treatment of schizophrenia with aripiprazole, asenapine and lurasidone: a meta-analysis. Curr Neuropharmacol. 2015; 13(5): 681–691
51. Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines in psychiatry, 12th edn. Hoboken, NJ: Wiley Blackwell, 2015
52. Adler L, Angrist B, Peselow E. A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. Br J Psychiatry. 1986; 149: 42–45
53. Poyurovsky M, Pashinian A, Weizman R. Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial. Biol Psychiatry. 2006; 59(11): 1071–1077
54. Adler LA, Peselow E, Rosenthal M. A controlled comparison of the effects of propranolol, benztropine, and placebo on akathisia: an interim analysis. Psychopharmacol Bull. 1993; 29(2): 283–286
55. Dumon JP, Catteau J, Lanvin F. Randomized, double-blind, crossover, placebo-controlled comparison of propranolol and betaxolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry. 1992; 149(5): 647–650
56. Irwin M, Sullivan G, Van Putten T. Propranolol as a primary treatment of neuroleptic-induced akathisia. Hillside J Clin Psychiatry. 1988; 10(2): 244–250
57. Kramer MS, Gorkin R, DiJohnson C. Treatment of neuroleptic-induced akathisia with propranolol: a controlled replication study. Hillside J Clin Psychiatry. 1989; 11(2): 107–119
58. Kramer MS, Gorkin RA, DiJohnson C. Propranolol in the treatment of neuroleptic-induced akathisia (NIA) in schizophrenics: a double-blind, placebo-controlled study. Biol Psychiatry. 1988; 24(7): 823–827
59. Fischel T, Hermesh H, Aizenberg D. Cyproheptadine versus propranolol for the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study. J Clin Psychopharmacol. 2001; 21(6): 612–615
60. Adler LA, Angrist B, Rotrosen J. Metoprolol versus propranolol. Biol Psychiatry. 1990; 27(6): 673–675
61. Avital A, Gross-Isseroff R, Stryjer R. Zolmitriptan compared to propranolol in the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study. Eur Neuropsychopharmacol. 2009; 19(7): 476–482
62. Adler L, Angrist B, Peselow E. Noradrenergic mechanisms in akathisia: treatment with propranolol and clonidine. Psychopharmacol Bull. 1987; 23(1): 21–25
63. Wells BG, Cold JA, Marken PA. A placebo-controlled trial of nadolol in the treatment of neuroleptic-induced akathisia. J Clin Psychiatry. 1991; 52(6): 255–260
64. Sachdev P, Loneragan C. Intravenous benztropine and propranolol challenges in acute neuroleptic-induced akathisia. Clin Neuropharmacol. 1993; 16(4): 324–331
65. Adler L, Reiter S, Corwin J. Differential effects of propranolol and benztropine in patients with neuroleptic-induced akathisia. Psychopharmacol Bull. 1987; 23: 519–521
66. DiMascio A, Bernardo DL, Greenblatt DJ. A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry. 1976; 33(5): 599–602
67. Baskak B, Atbasoglu EC, Ozguven HD. The effectiveness of intramuscular biperiden in acute akathisia: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2007; 27(3): 289–294
68. Friis T, Christensen TR, Gerlach J. Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia. A double-blind cross-over study with placebo. Acta Psychiatr Scand. 1983; 67(3): 178–187
69. Hirose S, Ashby CR. Intravenous biperiden in akathisia: an open pilot study. Int J Psychiatry Med. 2000; 30(2): 185–194
70. Miller CH, Fleischhacker WW. Managing antipsychotic-induced acute and chronic akathisia. Drug Saf. 2000; 22(1): 73–81
71. Poyurovsky M, Weizman A. Treatment of antipsychotic-related akathisia revisited: the role of serotonin 2a receptor antagonists. J Clin Psychopharmacol. 2015; 35(6): 711–714
72. Miodownik C, Lerner V, Statsenko N. Vitamin B6 versus mianserin and placebo in acute neuroleptic-induced akathisia: a randomized, double-blind, controlled study. Clin Neuropharmacol. 2006; 29(2): 68–72
73. Poyurovsky M, Shardorodsky M, Fuchs C. Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. Double-blind, placebo-controlled study. Br J Psychiatry. 1999; 174: 238–242
74. Poyurovsky M, Epshtein S, Fuchs C. Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study. J Clin Psychopharmacol. 2003; 23(3): 305–308
75. Stryjer R, Rosenzcwaig S, Bar F. Trazodone for the treatment of neuroleptic-induced acute akathisia: a placebo-controlled, double-blind, crossover study. Clin Neuropharmacol. 2010; 33(5): 219–222
76. Kutcher S, Williamson P, MacKenzie S. Successful clonazepam treatment of neuroleptic-induced akathisia in older adolescents and young adults: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 1989; 9(6): 403–406
77. Pujalte D, Bottai T, Hue B. A double-blind comparison of clonazepam and placebo in the treatment of neuroleptic-induced akathisia. Clin Neuropharmacol. 1994; 17(3): 236–242
78. Lerner V, Bergman J, Statsenko N. Vitamin B6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2004; 65(11): 1550–1554
79. Bendich A, Cohen M. Vitamin B6 safety issues. Ann N Y Acad Sci. 1990; 585: 321–330
80. Perry TA, Weerasuriya A, Mouton PR. Pyridoxine-induced neurotoxicity in rats: a stereological quantification of the sensory neuropathy. Exp Neurol. 2004; 190(1): 133–144
81. Sachdev P, Loneragan C. Low-dose apomorphine challenge in tardive akathisia. Neurology. 1993; 43(3 Pt 1): 544–547
82. Zubenko GS, Cohen BM, Lipinski JF, Jr. Use of clonidine in treating neuroleptic-induced akathisia. Psychiatry Res. 1984; 13(3): 253–259
83. Pfeffer G, Chouinard G, Margolese HC. Gabapentin in the treatment of antipsychotic-induced akathisia in schizophrenia. Int Clin Psychopharmacol. 2005; 20(3): 179–181
84. De Berardis D, Serroni N, Moschetta FS. Reversal of aripiprazole induced tardive akathisia by addition of pregabalin. J Neuropsychiatry Clin Neurosci. 2013; 25(2): E9–E10
85. Winkelman JW, Armstrong MJ, Allen RP. Practice guideline summary: treatment of restless legs syndrome in adults: report of the guideline development, dissemination, and implementation subcommittee of the american academy of neurology. Neurology. 2016; 87(24): 2583–2593